Last reviewed · How we verify
NCT06354556
Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects
Phase 1 trial testing HRS-1893 tablet in Obstructive Hypertrophic Cardiomyopathy in 14 participants. Completed in 20 May 2024.
20 May 2024
Quick facts
| Lead sponsor | Shandong Suncadia Medicine Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 14 |
| Start date | 26 April 2024 |
| Primary completion | 20 May 2024 |
| Estimated completion | 20 May 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- HRS-1893 tablet
- Verapamil tablet
Conditions studied
- Obstructive Hypertrophic Cardiomyopathy — all drugs for Obstructive Hypertrophic Cardiomyopathy →
Sponsor
Shandong Suncadia Medicine Co., Ltd. — full company profile →
Who can join
Adults 18 to 55, any sex, with Obstructive Hypertrophic Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this phase Ⅰ study is to evaluate the effect of oral verapamil tablets on the pharmacokinetics of HRS-1893 in healthy subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06354556
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obstructive Hypertrophic Cardiomyopathy
Currently open trials in the same condition.
- NCT07023341 — A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic · Phase 3 · active not recruiting
- NCT06146660 — A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy · recruiting
- NCT06551129 — Real-world Patient Reported Outcomes Among Patients Treated With Camzyos · recruiting
- NCT06023186 — Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM · recruiting
- NCT05489705 — A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes · recruiting
Other Shandong Suncadia Medicine Co., Ltd. trials
Trials by the same sponsor.
- NCT07272330 — A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects · Phase 1 · completed
- NCT07269756 — A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese · Phase 1 · completed
- NCT07229560 — A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy Participants · Phase 1 · completed
- NCT07097831 — A Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects · Phase 1 · completed
- NCT06961643 — Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic Function · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06354556 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong Suncadia Medicine Co., Ltd.
- Last refreshed: 6 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06354556.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing